跳至主要内容
临床试验/NCT06376591
NCT06376591已完成不适用

Assessing the Efficacy of Different Carrier Systems in Oral Vitamin B12 Supplementation in Improving Circulatory B12 Levels in Healthy Adults

Liaquat University of Medical & Health Sciences2 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2024年4月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
70
试验地点
2
主要终点
Supplementation effect on circulatory vitamin B12 levels

研究概览

简要总结

Vitamin B12, a vital nutrient, plays a crucial role in red blood cell formation, neurological function, and DNA synthesis. Deficiency in B12 can lead to anemia, neurological symptoms such as tingling or numbness, and cognitive impairment. Oral B12 supplementation serves as an effective strategy to address B12 deficiency, especially for individuals with limited dietary intake or absorption issues. Regular B12 supplementation can help restore body B12 levels, alleviate deficiency-related symptoms, and support overall health and well-being.

详细描述

The carrier system in oral vitamin B12 supplements plays a pivotal role in ensuring the stability and efficacy of the supplement. It helps protect the vitamin from degradation in the acidic environment of the stomach, enhancing its bioavailability. Additionally, the carrier system facilitates the transport of vitamin B12 across the gastrointestinal tract, promoting optimal absorption. By optimizing the delivery of B12 to the small intestine, the carrier system maximizes its potential for absorption into the bloodstream. Overall, the choice of carrier system significantly impacts the effectiveness of oral B12 supplementation in addressing deficiency and improving health outcomes.

Limited research exists regarding the exploration of various carrier systems used in oral B12 supplementation. This gap hinders a comprehensive understanding of how different carriers affect B12 absorption and efficacy. Further studies are needed to elucidate the optimal carrier system for maximizing B12 bioavailability and improving clinical outcomes. Expanding research in this area can enhance our knowledge and guide the development of more effective oral B12 supplements.

This study aims to compare the efficacy of sucrosomial and non-sucrosomial carrier systems in delivering vitamin B12 orally. By assessing absorption kinetics and clinical outcomes, we seek to determine the superiority of the sucrosomial carrier system in enhancing B12 bioavailability. Insights from this research could help in the development of more effective oral B12 supplements.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy adults, male or female, Aged 18 to 45 years
  • Stable medical conditions, including stable cardiovascular, renal, hepatic, and hematological status,
  • Normal vital signs Body mass index (BMI) 18-30 kg/m2
  • Suboptimal vitamin B12 status, defined as serum B12 levels within the lower end of the reference range established by the laboratory conducting the assay.
  • Willing and able to provide informed written consent.
  • Able to comply with study procedures and follow-up visits as outlined in the protocol.

排除标准

  • Known hypersensitivity or allergy to vitamin B12 or any of its components
  • Known history of cobalt allergy or sensitivity.
  • Severe malabsorption syndromes, including pernicious anemia or intestinal disorders affecting vitamin B12 absorption
  • History of gastric bypass surgery or other procedures that significantly alter gastrointestinal anatomy or function
  • Significant renal impairment (eGFR < 30 mL/min/1.73m²) or hepatic impairment
  • Uncontrolled or significant cardiovascular disease, including recent myocardial infarction, unstable angina, or heart failure
  • History of psychiatric illness or cognitive impairment that may impair their ability to comply with study procedures or provide informed consent
  • Currently enrolled in another clinical trial involving investigational products or interventions.
  • Pregnant or breast-feeding women
  • Current use of acetaminophen, or nonsteroidal anti-inflammatory drugs, antibiotics, antacids, PPIs, multivitamins, or nutritional supplements with Vit B12
  • Any other medical condition or circumstance that, in the investigator's judgment, would compromise the safety of the participant or the integrity of the study

结局指标

主要结局

Supplementation effect on circulatory vitamin B12 levels

时间窗: Day 1, Day 3, Day 5, Day 7

Changes in serum vitamin B12 levels

次要结局

  • Incidence of Treatment-Emergent Adverse Effects(one-week)

研究者

发起方
Liaquat University of Medical & Health Sciences
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Amjad Khan

Professor of Clinical Biochemistry and Experimental Medicine

Liaquat University of Medical & Health Sciences

研究点 (2)

Loading locations...

相似试验